“Last year was transformational for Candel, driven by our team’s incredible focus and execution of the Company’s key priorities,” said Paul Peter Tak, FMedSci, president and CEO of Candel. “We delivered positive data across our platforms, including pivotal topline phase 3 data for CAN-2409 in intermediate-to-high-risk localized prostate cancer in December, which we believe shows the potential of CAN-2409, if approved, to redefine the current standard of care for patients with prostate cancer.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CADL:
- Candel Therapeutics price target raised to $25 from $20 at Canaccord
- Promising Potential of Candel Therapeutics’ CAN-2409: Analyst Recommends ‘Buy’ Based on Compelling Phase 2 Trial Results and Future Outlook
- Candel Therapeutics Reports Positive Phase 2 Trial Results
- Candel Therapeutics announces overall survival data from Phase 2 CAN-2409 trial
- Walmart reports Q4 beat, Salesforce in cloud talks with Microsoft: Morning Buzz